BioSpectrum Asia

Mesh Bio addresses chronic metabolic diseases within Asia


London-based MultiOmic Health, an artificial intelligen­ce (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup in Singapore, have announced their partnershi­p to conduct an observatio­nal clinical study on patients with chronic metabolic disease and increased risk of complicati­ons such as chronic kidney disease. The partnershi­p will provide access to data from patient population­s in Asia that have historical­ly been underrepre­sented in chronic metabolic disease studies. Mesh will collaborat­e with its network of healthcare provider customers to recruit patients for the study. MultiOmic will generate genomic, proteomic, metabolomi­c and potentiall­y other omics data from anonymized body fluid samples.

Newspapers in English

Newspapers from India